We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

71 hedge funds and large institutions have $75.4M invested in Invesco Biotechnology & Genome ETF in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 11

0.95% more ownership

Funds ownership: 29.06% → 30.01% (+0.95%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 74 → 71 (-3)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

19% less capital invested

Capital invested by funds: $93.2M → $75.4M (-$17.8M)

Holders
71
Holders Change
-3
Holders Change %
-4.05%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
22
Reduced
11
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$6.12M
2
Morgan Stanley
Morgan Stanley
New York
+$2.67M
3
RJA
Raymond James & Associates
Florida
+$1.9M
4
Bank of America
Bank of America
North Carolina
+$1.76M
5
PA
PFG Advisors
Arizona
+$1.59M

Top Sellers

Rank Fund Capital Flow
1
ACM
Arlington Capital Management
Illinois
-$14.3M
2
UBS Group
UBS Group
Switzerland
-$2.23M
3
SG Americas Securities
SG Americas Securities
New York
-$452K
4
BRF
B. Riley Financial
California
-$415K
5
EA
Evanston Advisors
Illinois
-$238K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPIA
26
Steward Partners Investment Advisory
New York
$600K -$30.4K -591 -4%
RJFSA
27
Raymond James Financial Services Advisors
Florida
$559K +$39.3K +765 +7%
WBG
28
Wharton Business Group
Pennsylvania
$490K – – –
AG
29
Advisor Group
Arizona
$473K +$156K +3,034 +43%
Janney Montgomery Scott
30
Janney Montgomery Scott
Pennsylvania
$428K +$15.4K +300 +3%
FHA
31
Flagship Harbor Advisors
Massachusetts
$383K – – –
MML Investors Services
32
MML Investors Services
Massachusetts
$374K +$34K +662 +9%
SAM
33
SignalPoint Asset Management
Missouri
$356K – – –
BRWM
34
B. Riley Wealth Management
Tennessee
$355K +$388K +7,548 New
JIC
35
Joel Isaacson & Co
New York
$350K – – –
CA
36
Calton & Associates
Florida
$325K +$355K +6,899 New
BTS
37
BB&T Securities
Virginia
$244K +$7.71K +150 +3%
Citigroup
38
Citigroup
New York
$242K +$38K +740 +17%
Citadel Advisors
39
Citadel Advisors
Florida
$233K +$254K +4,950 New
IHL
40
Investment House LLC
California
$233K +$254K +4,950 New
SWP
41
Stratos Wealth Partners
Ohio
$232K +$207K +4,027 +443%
CIC
42
Carnegie Investment Counsel
Ohio
$227K -$26.5K -515 -10%
OC
43
Oppenheimer & Co
New York
$227K +$5.14K +100 +2%
UCFA
44
United Capital Financial Advisors
Texas
$218K +$5.14K +100 +2%
WB
45
Webster Bank
Connecticut
$192K – – –
NFG
46
Next Financial Group
Texas
$162K +$105K +2,035 +145%
Carson Wealth (CWM LLC)
47
Carson Wealth (CWM LLC)
Nebraska
$151K – – –
IA
48
IFP Advisors
Florida
$94K -$11.6K -225 -10%
JCM
49
Jacobi Capital Management
Pennsylvania
$56K – – –
PNC Financial Services Group
50
PNC Financial Services Group
Pennsylvania
$50K – – –
1
2
3 4

PBE Hedge Fund Activity: Q4 2018 in Review

71 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2018, worth a combined $75.4M — down 19% from $93.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PBE and 13 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 22 added.

The largest buyer was HighTower Advisors, adding an estimated $6.12M. The largest seller was Arlington Capital Management, cutting an estimated $14.3M.

  • 71 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2018, down from 74 in Q3 2018.
  • Funds reported $75.4M of Invesco Biotechnology & Genome ETF stock for Q4 2018, down 19% quarter-over-quarter.
  • 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2018 and 16 closed out, a net change of -3 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2018 was HighTower Advisors, an estimated $6.12M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2018 was Arlington Capital Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q4 2018.